Table 3.

Some studies that evaluated probiotics used in the treatment of UTIs^[42]

Agents used	Dose, and route of administration	Number of patients, and structure of the study	Efficacy in conditions of UTI	RR (95% CI) p	Reference
Antimicrobial treatment and Lactobacillus ovules	Vaginal, >1.6×109 CFU/L. rhamnosus GR-1 and L.fermentum B-54	Randomized placebo-controlled, double-blind study including 41 pre-, and postmenopausal patients	Recurrence rate: 29% in UTI patients receiving antimicrobial treatment Recurrence rate was observed to be 21% in patients who received vaginal ovules containing Lactobacillus spp. following antimicrobial treatment	0.45 (0.15–1.40) p=0.2682	47
Lactobacillus rhamnosus GR-1 ve Lactobacillus reuteri B-54	Vajinal, 1×109 CFU/L. rhamnosus GR-1 ve L.fermentum B-54	55 pre-menopausal women; randomized double-blind study	Recurrence rate was 73% in 25 patients who received once weekly doses of vaginal ovules containing L. rhamnosus GR-1 ve L.reuteri B-54; 79% decrease was observed in recurrence rates in 30 patients who received once weekly doses of intravaginal lactobacillus growth factor	Not performed	48
Lactobacillus drink, and fruit juice	Oral, 4×1010 CFU/100 mL. rhamnosus GG	324 pre-menopausal patients, randomized placebo-controlled double-blind study	The risk of UTI decreased significantly using fruit juice containing probiotic in 139 patients diagnosed as acute UTI.	1.11 (0.70–1.76) p=0.8320	49
Lactobacillus ovules	Vaginal, 108 CFUs/mL L. crispatus	100 premenopozal, Randomized placebo-controlled, double-blind study including 100 premenopausal women	Vaginal ovule containing L. crispatus, and placebo were applied for 10 weeks in patients who did not receive UTI treatment within the previous 12, and a significant decrease in disease was observed in the probiotic group	0.54 (0.24–1.23) p=0.2089	16